Porton Pharma Solutions Ltd. (SHE:300363)
20.18
-0.84 (-4.00%)
Nov 20, 2026, 3:04 PM CST
Porton Pharma Solutions Revenue
Porton Pharma Solutions had revenue of 974.81M CNY in the quarter ending September 30, 2026, with 5.56% growth. This brings the company's total for the last twelve months to 3.64B, up 6.09% year-over-year. In the year 2025, Porton Pharma Solutions had annual revenue of 3.42B with 13.54% growth. That makes Porton Pharma Solutions the 10,770th largest company in the world by revenue and 1,787th in China.
Revenue (ttm)
3.64B
Revenue Growth
+6.09%
P/S Ratio
2.97
Revenue / Employee
835.08K
Employees
4,400
Market Cap
10.82B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Porton Pharma Solutions breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.42B | 407.86M | 13.54% |
| Dec 31, 2024 | 3.01B | -655.45M | -17.87% |
| Dec 31, 2023 | 3.67B | -3.37B | -47.87% |
| Jan 1, 2023 | 7.03B | 3.93B | 126.55% |
| Jan 1, 2022 | 3.11B | 1.03B | 49.87% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harbin Pharmaceutical Group | 16.30B |
| Shanghai Shyndec Pharmaceutical | 8.03B |
| Zhejiang CONBA Pharmaceutical | 6.83B |
| Guobang Pharma | 6.13B |
| Shenzhen Hepalink Pharmaceutical Group | 5.08B |
| Mayinglong Pharmaceutical Group | 3.99B |
| Shenyang Xingqi Pharmaceutical | 2.81B |
| Beijing Aosaikang Pharmaceutical | 1.59B |